In the phase 3 ACHIEVE-3 trial , adults with type 2 diabetes inadequately controlled by metformin were randomized to receive orforglipron or oral semaglutide (7 mg and 14 mg, doses approved for type 2 diabetes)
Materials Science and Engineering: C
Clinical efficacy Zepbound is currently considered the most efficient weight-loss injection
64 Through real-time monitoring of vital signs, physiological parameters, and other health-related data, digital twins possess the capability to detect early signs of deterioration or anomalies
So, were talking about effective treatment, and we see that these compounds, administering them together, could lead to a possible pharmaceutical option for treating Type 2 diabetes, he says